Basically we (much like Triangle) are trying to avoid benign lumped into the crazy category. The market potential at 3% penetration is already ludicrous so going beyond this is just counterproductive.
The amazing thing is we could sell RC220 bisantrene priced as a generic (i.e the same as doxorubicin) and we would still be a multiple billion dollar company. I doubt there is another biotech company in the world that could claim that.
Ann: Race to Present at TechKnow July Conference, page-56
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.46 | $143.9K | 96.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 230 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 550 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |